Middle East and Africa Biosimilars Market Forecast to 2035 - Industry Trends and Competitive Analysis | Patent Expiries Drive 19% CAGR and a USD 5.73 Billion Opportunity
Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Middle East and Africa Biosimilars Market: Industry Trends and Global Forecasts - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players" has been added to ResearchAndMarkets.com's offering.
Middle East and Africa Biosimilars Market Poised to Reach USD 5.73 Billion by 2035
The Middle East and Africa biosimilars market is projected to grow from USD 1.15 billion in the current year to USD 5.73 billion by 2035, representing a CAGR of 19% during the forecast period. Market expansion is being supported by patent expirations for major biologic therapies, rising demand for cost-effective treatments, and increasing healthcare investment across the region.
Market Growth and Key Trends
The growing prevalence of cancer, diabetes, autoimmune disorders, and other chronic diseases is increasing demand for biologic therapies throughout the Middle East and Africa. However, the high cost of originator biologics continues to restrict patient access and place pressure on public healthcare budgets. Biosimilars address this challenge by expanding treatment availability while supporting healthcare cost management.
Saudi Arabia, the UAE, and South Africa are among the prominent markets benefiting from favorable regulatory developments, government procurement programs, and healthcare modernization. Governments and healthcare authorities are encouraging biosimilar adoption through tenders, incentives, and streamlined approval pathways. These measures are expected to improve access to treatment and create commercial opportunities for regional and international manufacturers.
Patent expirations for leading biologics, including Herceptin and Rituxan, are also enabling manufacturers to expand their product portfolios. Strategic partnerships with global pharmaceutical companies, low-cost manufacturing capabilities, and access to skilled professionals are strengthening the region's role in biosimilar development, production, and distribution.
Market Challenges
Despite a strong growth outlook, the Middle East and Africa biosimilars market faces several barriers. High development expenses, complex production requirements, stringent quality controls, immunogenicity risks, and structural variability can limit participation by smaller companies. Evolving regulatory frameworks and comparative clinical trial requirements may also extend approval timelines.
Limited domestic manufacturing and R&D infrastructure in parts of the region contributes to import dependency and potential supply disruptions. Additional constraints include pricing pressure, competition from branded generics, patent litigation initiated by originator companies, and uneven market access across individual countries.
Leading Market Segments
Monoclonal antibodies currently account for approximately 55% of the Middle East and Africa biosimilars market. Their leading position is supported by extensive use in treating cancer, rheumatoid arthritis, and autoimmune disorders. The peptide segment, however, is forecast to register a faster CAGR during the forecast period.
Oncological disorders represent the leading therapeutic area. An aging population, lifestyle changes, improved diagnostic capabilities, and demand for affordable cancer therapies are creating opportunities for biosimilar developers. Hematological disorders are expected to record a higher CAGR through 2035.
The market is analyzed across the following segments:
Competitive Landscape
Companies active in the Middle East and Africa biosimilars market include AbbVie, Amgen, Biocon, Celltrion Healthcare, Dr. Reddy's Laboratories, Pfizer, Roche, Samsung Bioepis, Sandoz, Teva Pharmaceutical Industries, and Viatris. Competition is expected to intensify as manufacturers pursue regulatory approvals, regional partnerships, portfolio expansion, and localized production strategies.
Insights Provided by the Report
The report evaluates the current and projected Middle East and Africa biosimilars market size, country-level performance, competitive positioning, growth drivers, regulatory trends, adoption barriers, and emerging commercial opportunities. It also assesses how market revenue is expected to be distributed across drug classes, therapeutic areas, manufacturer types, and distribution channels.
Stakeholders can use the findings to evaluate customer demand, identify attractive market segments, monitor changing competitive conditions, and develop data-driven market entry or expansion strategies. The analysis is designed to support established pharmaceutical companies, biosimilar developers, contract manufacturers, investors, distributors, healthcare organizations, and new market entrants.
Complementary Benefits
Key Attributes:
Key Topics Covered:
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Biologics
6.3. Overview of Biosimilars and Biobetters
6.4. Difference between Innovator Biologics, Biosimilars and Generics
6.5. Advantages of Biosimilars
6.6. Manufacturing of Biosimilars
6.7. Development Timeline of Biosimilars
6.8. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Biosimilars: Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters (Region)
7.2.4. Analysis by Location of Headquarters (Country)
7.3. Biosimilars: Overall Market Landscape
7.3.1. Analysis by Stage of Development
7.3.2. Analysis by Therapeutic Area
7.3.3. Analysis by Drug Class
8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Biosimilars Providers in Middle East and Africa: Company Competitiveness Analysis
8.4.1. Small Biosimilar Developers (Peer Group I)
8.4.2. Mid-sized Biosimilar Developers (Peer Group II)
8.4.3. Large Biosimilar Developers (Peer Group III)
8.5. Capability Benchmarking of top Biosimilar Developers
9. COMPANY PROFILES: MIDDLE EAST AND AFRICA BIOSIMILARS MARKET
9.1. Chapter Overview
9.2. Amgen
9.2.1. Company Overview
9.2.2. Product Portfolio
9.2.3. Financial Information
9.2.4. Recent Developments and Future Outlook
9.3. Roche
9.4. Sandoz
9.5. Dr. Reddy's Laboratories
9.6. Teva Pharmaceutical Industries
9.7. Pfizer
9.8. Samsung Bioepis
9.9. Biocon
9.10. Viatris
9.11. Celltrion Healthcare
9.12. AbbVie
10. COST PRICE ANALYSIS
10.1. Chapter Overview
10.2. Factors Contributing to High Price of Novel Biologics
10.3. Pricing of Biosimilars
10.3.1. Price Comparison of Different Biosimilars with its Reference Biologic
10.4. Concluding Remarks
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.2.1. Global Annual Demand for Biosimilars
11.2.1.1. Analysis by Drug Class
11.2.1.2. Analysis by Therapeutic Area
11.2.1.3. Analysis by Type of Manufacturer
11.2.1.4. Analysis by Distribution Channel
11.2.1.5. Analysis by Geographical Regions
12. MARKET IMPACT ANALYSIS
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
13. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Middle East and Africa Biosimilars Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.4. Analyst's Perspective on Market Growth
13.5. Scenario Analysis
13.5.1. Conservative Scenario
13.5.2. Optimistic Scenario
13.6. Key Market Segmentations
14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY DRUG CLASS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Middle East and Africa Biosimilars Market: Distribution by Drug Class
14.3.1. Middle East and Africa Biosimilars Market for Monoclonal Antibodies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
14.3.2. Middle East and Africa Biosimilars Market for Proteins, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
14.3.3. Middle East and Africa Biosimilars Market for Peptides, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
14.3.4. Middle East and Africa Biosimilars Market for Others, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
14.4. Data Triangulation and Validation
15. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY THERAPEUTIC AREA
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Middle East and Africa Biosimilars Market: Distribution by Therapeutic Area
15.3.1. Middle East and Africa Biosimilars Market for Oncological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.3.2. Middle East and Africa Biosimilars Market for Autoimmune and Inflammatory Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.3.3. Middle East and Africa Biosimilars Market for Hematological Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.3.4. Middle East and Africa Biosimilars Market for Metabolic Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.3.5. Middle East and Africa Biosimilars Market for Other Disorders, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
15.4. Data Triangulation and Validation
16. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY TYPE OF MANUFACTURER
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Middle East and Africa Biosimilars Market: Distribution by Type of Manufacturer
16.3.1. Middle East and Africa Biosimilars Market for Contract Manufacturers, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
16.3.2. Middle East and Africa Biosimilars Market for In-house Developers, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
16.4. Data Triangulation and Validation
17. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Middle East and Africa Biosimilars Market: Distribution by Distribution Channel
17.3.1. Middle East and Africa Biosimilars Market for Hospital Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
17.3.2. Middle East and Africa Biosimilars Market for Retail Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
17.3.3. Middle East and Africa Biosimilars Market for Online Pharmacies, Historical Trends (Since 2022) and Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation
18. CONCLUDING REMARKS
19. APPENDIX I: TABULATED DATA
20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/e8j1jx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.